Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 34, Issue 10, Pages 1193-1201
Publisher
Wiley
Online
2011-09-30
DOI
10.1111/j.1365-2036.2011.04860.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
- (2010) Yu-Yun Shao et al. CANCER
- Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma
- (2010) Markus Peck-Radosavljevic et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib
- (2010) Violaine Ozenne et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study
- (2010) R. Lencioni et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
- (2010) Yujin Hoshida et al. SEMINARS IN LIVER DISEASE
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Review article: the management of hepatocellular carcinoma
- (2009) R. CABRERA et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Evaluation of Response in Malignant Tumors Treated With the Multitargeted Tyrosine Kinase Inhibitor Sorafenib: A Multitechnique Imaging Assessment
- (2009) Olga Maksimovic et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib
- (2009) Marius Horger et al. BMC CANCER
- Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma
- (2009) Alejandro Forner et al. CANCER
- Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis
- (2009) Marcus Alexander Wörns et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Role of sorafenib in HCC patients with compromised liver function
- (2009) Massimo Di Maio et al. Nature Reviews Clinical Oncology
- Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis
- (2009) M. Pinter et al. ONCOLOGIST
- Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents
- (2008) M. CHAPARRO et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy
- (2008) Stephen L. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now